Net income surged 85% year-over-year to $15.4 million.
Gross margins dropped from 51% to 48% due to price compression and licensing fees.
Expanded share repurchase program to $150 million.
Increased syndicated credit facility to $200 million to support liquidity.
The Q1 2026 filing presents a company at a crossroads between operational maturity and structural risk. On one hand, the explosive growth in net income and the move toward fixed licensing costs suggest a business that has found its footing and is ready to scale efficiently. On the other, the divergence between rising costs and modest revenue growth indicates that price compression is a real and present danger in the competitive cannabis landscape. Ultimately, the investment thesis hinges on two primary factors: the execution of the retail expansion and the timing of federal regulatory shifts. If the DOJ's rescheduling of marijuana to Schedule III materializes, the resulting tax relief would be a generational catalyst for the company's bottom line. However, until that occurs, investors must weigh the benefit of aggressive buybacks against the risk of a debt-to-EBITDA ratio that leaves the company with very little margin for operational volatility.